培美曲塞与多西他赛联合化疗治疗晚期非小细胞肺癌_许涛

组发生了2例Ⅱ－Ⅲ度肺炎，因此乳腺癌保乳术后照射时，应用IMRT 技术要权衡利弊，尽量避免多野、多子野技术。

【参考文献】［1］Early breast cancer trialists＇collaborative group （EBCTCG ）．Effectsof radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15－year survival ：an over-view of the randomised trials ［J ］．Lancet ，2005，366：2087－2106．［2］Vicini FA ，Sharpe M ，Kestin L ，et al．Optimizing breast cancer treatmentefficacy with intensity －modulated radiotherapy ［J ］．Int J Radiat Oncol Biol Phys ，2002，54（5）：1336－1344．［3］Beckham WA ，Popescu CC ，Patenaude VV ，et al．Is multibeam IM-RT better than standard treatment for patients with left －sided breast cancer ［J ］？Int J Radiat Oncol Biol Phys ，2007，69（3）：918－927．［4］Mcdonald MW ，Godette KD ，Butker EK ，et al．Long －term out-comes of IMRT for breast cancer ：A single －institution cohort a-nalysis ［J ］．Int J Radiat Oncol Biol Phys ，2008，72（4）：1031－1040．［5］Pignol JP ，Olivotto I ，Rakovitch E ，et al．A multicenter randomized trialof breast intensity －modulated radiation therapy to reduce acute radi-ation dermatitis ［J ］．J Clin Oncol ，2008，26（13）：2085－2092．［6］Freedman GM ，Li T ，Nicolaou N ，et al．Breast intensity modulatedradiation therapy reduces time spent with acute dermatitis for women of all breast sizes during radiation ［J ］．Int J Radiat Oncol Biol Phys ，2009，74（3）：689－694．［7］Harsolia A ，Kestin L ，Grills I ，et al．Intensity －modulated radiother-apy results in significant decrease in clinical toxicities compared with conventional wedge －based breast radiotherapy ［J ］．Int J Ra-diat Oncol Biol Phys ，2007，68（5）：1375－1380．［8］Krengli M ，Sacco M ，Loi G ，et al．Pulmnary changes after radiother-apy for conserative treatment of breast cancer ：a prospective study ［J ］．Int J Radiat Oncol Biol Phys ，2008，70（5）：1460－1467．［9］Varga Z ，Cserhati A ，Kelemen G ，et al．Role of systemic in the de-velopment of lung sequelae after conformal radiotherapy in breast cancer patients ［J ］．Int J Radiat Oncol Biol Phys ，2011，80（4）：1109－1116．［10］Holli K ，Pitkanen M ，Jarvenpaa R ，et al．Early skin and lung reac-tions in breast cancer patients after radiotherapy ：prospective study ［J ］．Radiother Oncol ，2002，64：163－169．［11］Lee HK ，Cox JD ，Vaporciyan AA ，et al．Postoperative pulmonary com-plications after preoperative chemoradiation for esophageal carcino-ma ：correlation with pulmonary dose －volume histogram parameters ［J ］．Int J Radiat Biol Phys ，2003，57（5）：1317－1322．［12］Jaen J ，Vazquez G ，Alonso E ，et al．Changes in pulmonary function af-ter incidental lung irradiation for breast cancer ：A prospective study ［J ］．Int J Radiat Oncol Biol Phys ，2006，65（5）：1381－1388．［13］Wang SL ，Liao ZX ，Vaporciyan AA ，et al．Investigation of clinicaland dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concur-rent chemoradiotherapy followed by surgery ［J ］．Int J Radiat Oncol Biol Phys ，2006，64（3）：692－699．［14］Blom －Goldmen U ，Svane G ，Wennbegr B ，et al．Quantitative as-sessment of lung density changes after 3－D radiotherapy for breast cancer ［J ］．Acta Oncologica ，2007，46：187－193．［15］Tucker SL ，Jin H ，Wei X ，et al．Impact of toxicity grade and sco-ring system on the relationship between mean lung dose and risk of radiation pneumonitis in a large cohort of patients with no －small cell lung cancer ［J ］．Int J Radiat Oncol Biol Phys ，2010，77（3）：691－698．(编校:张西敏)培美曲塞与多西他赛联合化疗治疗晚期非小细胞肺癌许涛，李林均，张军，余建云，陈萍Observation of pemetrexed plus docetaxel in the treatment of advanced non －small －cell lung cancerXu Tao ，Li Linjun ，Zhang Jun ，Yu Jianyun ，Chen PingDepartment of Oncology ，People ＇s Hospital ，Hubei University of Medicine ，Hubei Shiyan 442000，China．【Abstract 】Objective :To explore the short －term curative effect ，side effects and survival time of pemetrexed plus docetaxel for advanced non －small －cell lung cancer (NSCLC )．Methods :Twenty eight patients with stage Ⅲb or ⅣNSCLC confirmed by pathology or cytology were treated with pemetrexed plus docetaxel．Patients received intravenous infusion of pemetrexed (500mg /m 2)and docetaxel (70－80mg /m 2)after admission．Treatment was repeated every 21【收稿日期】2012－01－22【修回日期】2012－02－15【作者单位】湖北医药学院附属人民医院肿瘤中心，湖北十堰442000【作者简介】许涛（1979－），男，湖北仙桃人，硕士，主治医师，主要从事恶性肿瘤的放化疗工作。

E －mail ：xutao19790804@163．com 【通讯作者】李林均（1979－），男，湖北丹江口人，副主任医师，主要从事恶性肿瘤的放化疗工作。

E －mail ：lilinjun@yahoo．com．cn·723·现代肿瘤医学2013年02月第21卷第2期MODERN ONCOLOGY ，Feb.2013，VOL.21，NO.02days．Response and toxicity were evaluated in patients who received two cycles of chemotherapy．Results：The re-sponse rate was21．4%，disease control rate was71．4%，time to progression was6．5months．Incidence rates ofⅠ/Ⅱʎeukocytopenia andⅢ/Ⅳʎeukocytopenia were53．6%and14．2%，and the incidence rate ofⅠ/Ⅱʎthrombocy-topenia was17．8%；The incidence rate of nausea and vomiting was50%，the incidence rate of constipation was 25%，and the incidence rate of weakness was64．3%．Conclusion：Patients have a high response rate and a low toxic-ity．Pemetrexed plus docetaxel can be used in treatment of NSCLC．【Key words】non－small－cell lung carcinoma（NSCLC）；lung neoplasms；pemetrexed；docetaxelModern Oncology2013，21（02）：0327－0330【摘要】目的：观察培美曲塞联合多西他赛方案治疗晚期非小细胞肺癌的近期疗效、毒副反应和生存期，探讨该方案的可行性。